Ipilimumab in cancer patients: the issue of early metabolic response

Anti-Cancer Drugs

Volumn 24, Issue 3, 2013, Pages 324-326

  Chargari, Cyrus ^a   Le Moulec, Sylvestre ^a   Bonardel, Gérald ^a   Foehrenbach, Hervé ^a   Védrine, Lionel ^a  

^a University of Paris Descartes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; TEMOZOLOMIDE;

AGED; BONE METASTASIS; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DERMATITIS; DRUG RESPONSE; GENERAL CONDITION IMPROVEMENT; HUMAN; LETTER; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; METABOLISM; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR FLARE; TUMOR VOLUME;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DERMATITIS; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84873401172     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835dbaaf     Document Type: Letter

References (8)

1. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012; 30:1628-1234
2. Robert C, Thomas L, Bondarenko I, O'Day S, JW MD, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526
3. Hodi FS, O'Day SJ, McDermott DF,Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
4. Wolchok JD, Hoos A, O'Day S,Weber JS, Hamid O, Lebbé C. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15:7412-7420
5. WeberJS,Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-2697
6. Deichen JT, Prante O, Gack M, Schmiedehausen K, Kuwert T. Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med Mol Imaging 2003; 30:267-273
7. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 2010; 51:340-346
8. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-Dioxygenase in patients with melanoma undergoing TLA4 blockade. Clin Cancer Res 2009; 15:390-399